Value
8.5/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 7.7 |
| Analyst target | 9.0 |
- ▸Attractively valued
STRO · Why this verdict
Why Sutro Biopharma (STRO) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score4.8/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Sutro Biopharma combines strong sentiment and a favorable risk/reward asymmetry with a below-floor quality score, declining revenue, and options pricing that reflects a binary, high-volatility biotech name.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Quality sits below the engine's floor at 3.2 versus a 4.0 minimum, with value-trap signals flagging margin compression (operating margin -33.1%) and material insider selling. Bear case | Operating margin should improve toward breakeven over the next several quarters as cash burn narrows. | ↓Deteriorating |
| CounterValue scoring separately flags the stock as attractively valued, suggesting the market may already be pricing in the margin weakness. | ||
Analysts see 57% upside with a strong sentiment score of 8.2, and the stock trades above its 200-day moving average with momentum at 7.5, comfortably clearing the engine's threshold. Sentiment breakdown | Price should close a meaningful share of the gap toward the $41.54 take-profit target over the next 12 months. | ↑Improving |
| CounterGrowth notes flag declining revenue at -16%, a fundamental headwind that could cap how far sentiment-driven upside actually travels. | ||
The engine's asymmetry ratio sits at 2.43, comfortably above the 1.5 gate, with 36.5% upside against 15% downside. Reward-to-risk math | The asymmetry ratio should stay above 2.0 as the favorable risk/reward setup persists. | →Stable |
| CounterThe suitability rationale flags this as a speculative, binary biotechnology name, where a single clinical or regulatory event could invalidate the current risk/reward math. | ||
Implied volatility is high at 175%, reflecting the options market's expectation of a large binary move in the stock. Risk breakdown | Implied volatility should moderate below 120% as uncertainty around key catalysts resolves. | ↓Deteriorating |
| CounterAs a small-cap, binary biotechnology name, persistently high implied volatility may simply be a structural feature of the stock rather than a temporary condition. | ||
Quality sits below the engine's floor at 3.2 versus a 4.0 minimum, with value-trap signals flagging margin compression (operating margin -33.1%) and material insider selling.
↓DeterioratingBear case
- Expectation
- Operating margin should improve toward breakeven over the next several quarters as cash burn narrows.
CounterValue scoring separately flags the stock as attractively valued, suggesting the market may already be pricing in the margin weakness.
Analysts see 57% upside with a strong sentiment score of 8.2, and the stock trades above its 200-day moving average with momentum at 7.5, comfortably clearing the engine's threshold.
↑ImprovingSentiment breakdown
- Expectation
- Price should close a meaningful share of the gap toward the $41.54 take-profit target over the next 12 months.
CounterGrowth notes flag declining revenue at -16%, a fundamental headwind that could cap how far sentiment-driven upside actually travels.
The engine's asymmetry ratio sits at 2.43, comfortably above the 1.5 gate, with 36.5% upside against 15% downside.
→StableReward-to-risk math
- Expectation
- The asymmetry ratio should stay above 2.0 as the favorable risk/reward setup persists.
CounterThe suitability rationale flags this as a speculative, binary biotechnology name, where a single clinical or regulatory event could invalidate the current risk/reward math.
Implied volatility is high at 175%, reflecting the options market's expectation of a large binary move in the stock.
↓DeterioratingRisk breakdown
- Expectation
- Implied volatility should moderate below 120% as uncertainty around key catalysts resolves.
CounterAs a small-cap, binary biotechnology name, persistently high implied volatility may simply be a structural feature of the stock rather than a temporary condition.
Per-dimension breakdown
Quality
3.2/10data confidence 71%| Component | Sub-score |
|---|---|
| ROA | 0.0 |
| Current ratio | 9.9 |
| FCF quality | 0.0 |
| Moat | 3.8 |
| Piotroski F | 2.2 |
- ▸Cash-burning: FCF -107% of revenue
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 2/9
Growth
0.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 0.0 |
- ▸Declining revenue: -16%
Momentum
4.6/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 8.5 |
| MACD | 0.0 |
| OBV | 10.0 |
| MA position | 4.0 |
| Volume | 0.3 |
- ▸Oversold in uptrend (RSI 22)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
8.0/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 8.4 |
| Price target | 10.0 |
| erm sentiment | 5.1 |
- ▸Analyst upside: 102%
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
- ▸Institutions accumulating
Peer rank
4.0/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 8.4 |
| quality rank | 0.0 |
| growth rank | 2.7 |
Technical
5.9/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 8.0 |
| support resistance | 8.9 |
| 52w position | 0.8 |
| gap | 6.0 |
Risk (lower is worse)
3.0/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 5.9 |
| days to cover | 7.4 |
| volatility | 0.0 |
| put call | 0.0 |
| implied vol | 0.0 |
| beta | 4.9 |
- ▸Elevated put/call: 2.67
- ▸High IV: 151%
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
4.2/10data confidence 75%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| surprise avg | 4.4 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Market cap $388M below $400M minimum. Not in investable universe.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:MARKET_CAPPassed (8)
- MOMENTUM:4.6>=4.5
- ASYMMETRY:5.1>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:NO_DATE
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (1)
- MOMENTUM:4.6<5.5 (soft — BUY_NOW allowed but watch)
Reward-to-Risk
5.07
Upside
+76.0%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($0.4B) below institutional reach
SuitabilitySpeculative — Drawdown -46% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The HOLD_IF_HOLDING verdict reflects clean gate clearance against Value at 8.5 and asymmetric R:R of 5.07.
The strongest dimensions are Value at 8.5, Sentiment at 8.0, and Insider at 7.3; the weakest are Growth at 0.0, Risk (lower is worse) at 3.0, and Quality at 3.2. The V9 engine cleared all gates with 1 warning, producing an asymmetric reward-to-risk of 5.07 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Analyst Upside Strong Momentum
Trip ifAnalyst upside estimate falls below 20% from the current 57%.
- P2Quality Floor Breach Cash Burn
Trip ifOperating margin stays below -20% for 2 consecutive quarters.
- P3Favorable Risk Reward Asymmetry
Trip ifAsymmetry ratio falls below 1.5, undoing the current 2.43 reading.
- P4Binary Volatility Pricing
Trip ifImplied volatility stays above 200% for 2 consecutive months.